Pharmaceutical Manufacturing in South Korea

Jw Pharmaceutical Corporation

JW Pharmaceutical Corp.(formerly Choongwae Pharma) is one of the leading pharmaceutical companies in Korea with core competencies in antibiotics, IV solutions, and anti-cancer treatments. JW is currently exploring targeted therapies in oncology leveraging the collaborative research and development strengths from the JW Drug Discovery Center in Korea and the JW Theriac Corp in the US. This R&D pipeline is driven by our platform technologies that have the potential to eradicate cancer stem cells selectively through a molecularly targeted approach- JW Group consists of JW Holdings, JW Pharmaceutical, JW Medical, JW ShinYak, JW Industrial, JW Life Science, and JW Creagene. JW possesses i) magnificent sales force (900 reps) for the hospital market, ii) strong relationships with managements of hospitals & and hospital pharmacies, excellent rapport with key opinion leaders in endocrinology, gastroenterology, oncology, cardiology, nephrology, urology and the general surgery therapeutic areas. JW's total sales revenue of US $ 0.7 billion was derived from Korea and other several Asian countries in 2012

1001 to 5000 staff

Celltrion Inc

Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics. We are committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. We have been at the forefront of biotherapeutic development uncovering new ways of targeting the drivers of disease by creating next-generation biologics and small molecule products. For additional information on our guidelines, please visit: https://bit.ly/4jv2wf2

1001 to 5000 staff

C&r Research, Inc

C&R Research is Korea’s first and leading CRO with over 28 years of experience. We have conducted over 1,800 clinical trials worldwide, proving our expertise and capabilities. Our experienced professionals and global clinical expertise empower us to deliver high-quality, cost-effective services. Subsidiaries in the U.S, Singapore, and Thailand enhance our support for multinational trials. Supported by a strong global network, C&R Research is expanding as a Korea-based global CRO, providing comprehensive clinical trial services that benefit clients worldwide.

501 to 1000 staff

Dong-A Pharmaceutical Co.,ltd

Dong-A Pharmaceutical Co, Ltd. Established in 1932, Dong-A Pharm. has been the leading pharmaceutical company in South Korea with its business focus in developing, manufacturing and distributing innovative products for the healthier life of our society. Headquartered in South Korea, Dong-A Pharm. employs over 2,300 people worldwide. Business portfolio: ETC, OTC + Bacchus (Energy Drink), Diagnostic & Medical Equipment, Bio-technology etc. For more information, please visit our website:

1001 to 5000 staff

Kolon Pharmaceutical, Inc

Kolon Pharmaceutical, Inc. was established in 1958 with a mission to contribute on happiness of mankind and social welfare by enhancing people’s quality of life and providing top medical service thru development of innovative drugs with its respect for life and health. Kolon Pharmaceutical is a subsidiary of Kolon group which is one of the biggest industrial conglomerates of Korea that has core business domains in pharmaceuticals, biotechnology, cutting-edge materials, fashion, construction, environment, trade and IT. Kolon group’s health business unit is composed of three subsidiaries and they are Kolon Pharmaceuticals, Kolon Life Science(biotechnology) and Kolon Wellcare(drug store business). Kolon Pharmaceutical developed many outstanding products like Bicogreen for constipation, cold remedy Comy syrup & tablet, anti-fungal drug Konitra and Tamsulo capsule for prostatism with its own technology and also co-developed Brexin tablet(β-Cyclodextrin Prioxicam), Remicut SR capsule(Emedastine difumarate) and Pransus syrup(Pranoprofen) with outstanding pharmaceutical companies like Chiesi, Hisamitsu and Organon since its establishment. Kolon Pharmaceutical is also expanding its global presence by exporting its quality products like Flavon(Ginko biloba ext.), Diverine(Gliclazide), Tavisin(Ofloxacin), Clovana(Diclofenac) and Turant(Acetylcysteine) to Vietnam, Pakistan, Yemen and many other Middle Eastern countries. Our continuous efforts led us to fruitful outcomes in significant areas of our business especially new molecule research, joint research, development of API, new formulation and combination new drug.

201 to 500 staff

Hk Inno-N

Since its establishment in 1984, HK inno.N Corp. has tapped into the belief that its business was also helping chart the nation’s future. This belief has served and continues to serve the company well, as it has grown into one of the leading pharmaceutical firms in the nation. Since its establishment in 1984, HK inno.N has gained competitiveness in the businesses of prescription drugs, active pharmaceutical ingredients, health supplements and beauty products. Drawing on the company’s experience and knowhow in developing novel drugs, HK inno.N succeeded in launching ‘K-CAB’, the 30th novel drug to be developed and registered in Korea, to great acclaim. Building on this success, HK inno.N remains committed to growing into a global bio health company built on outstanding products and technologies that bring us closer to a healthier future.

1001 to 5000 staff

Olix Pharmaceuticals, Inc

Accelerating Drug Development using Oligonucleotides Since its discovery, RNA interference (RNAi) technology has been widely recognized as a novel drug development platform that could change the paradigm of therapeutic development. OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on the science of RNAi to address a wide variety of illnesses. The Company has developed core platforms (asymmetric siRNA, cell-penetrating asiRNA) targeting locally administrable diseases, such as hypertrophic scars, hair loss, and age-related macular degeneration (AMD). OliX's third RNAi therapeutic platform, GalNAc-asiRNA, targets multiple liver diseases, including NASH/diabetes and HBV. For the general welfare of human beings, OliX is constantly endeavoring to become a leader in the global biotechnology industry by innovating and expanding its pipeline, even to the undruggable diseases.

51 to 200 staff

Yuyu Pharma

Yuyu Pharma (KRX was founded in 1941 and is a healthcare company located in Korea. The company is publicly traded since 1975. It manufactures, distributes, and does marketing for pharmaceutical products, medical devices, and medical foods in South Korea and Southeast Asia. The key therapeutic markets are CNS, Osteoporosis, Respiratory, and Urology. The R&D center has previously developed two unique improved medicines, Maxmarvil® for patients with osteoporosis and YUCLID® for anti-thrombosis. Currently, Yuyu Pharma has two new drug discovery programs targeting benign prostatic hyperplasia (BPH) and dry eye syndrome. Yuyu Pharma also has various Over-the-counter drugs and dietary supplements, such as YupanC® (vitamin C), Venoplus® (ointment), and Venapollo® (multivitamins)

201 to 500 staff

Sk Biopharmaceuticals

SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We’re responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at

201 to 500 staff

Kwangdong Pharmaceutical Co., Ltd

1963 ‘ ’, D, 50. ‘ C’ 500, 1. KD. ‘ ’ 2025 1, 1 4, TOM(Top of Mind) Brand ' ’.

1001 to 5000 staff

Nexus Pharma Co., Ltd

Nexus Pharma co, ltd. works to bring the global pharmaceutical community closer together. From small businesses to major pharmaceutical manufacturers, we bring you the highest quality of every pharmaceutical product available in Korea.

11 to 50 staff

Pharmaresearch Co. Ltd

PharmaResearch Co, Ltd. is a biopharmaceutical company leading the regenerative Rx, OTC, Medical Device, Cosmetics and Dietary supplement technology and their market.

201 to 500 staff

Servier Korea

SERVIER KOREA] Servier Korea was established in 1990 as a Korean affiliate of Servier. In order to serve patients’ treatment needs and medical unmet needs, Servier Korea is working on various disease areas including hypertension, diabetes, heart failure, angina, and oncology.

51 to 200 staff

Ckd Bio Corporation

CKD Bio Corporation CKD Bio is devoted to serving the better life through better medicines. with over-70-year experiences in the pharmaceutical industry. CKD Bio manufactures highest quality intermediates and APIs through fully integrated manufacturing process from fermentation to chemical synthesis. CKD Bio is specialized in Contract Manufacturing and Contract Research in the field of fermentation and chemical synthesis. CKD Bio is trying to open the next era by developing the latest and newest generation of pharmaceutical products such as antibiotics, anti-diabetics, anti-fungal and etc.

501 to 1000 staff

Daehwa Pharmaceutical Co., Ltd

DAEHWA was established on Jan. of 1984 and listed in KOSDAQ(Stock market) since 2002. We are running 3 R&D centers and 4 Manufacturing facilities with philosophy of Respecting life / Protection of environment / Advanced Technology that leads pharmaceutical industry. We are tries to contribute to the health and well-being of human race.*R&D Center - Pankyo R&D Center: Mainly research on DDS(Drug Delivery System)/Natural products - Central R&D Center: Mainly research on impovement of products(Formulation and others)- Hyangnam R&D Center: Mainly research on synthesizing of API and others *Manufacturing facility - 1st factory: Mainly manufacturing for oral formulations(Tab./ Cap./ ODF) and external agents as ointment, cream and gel- 2nd factory: Dedicated for manufacturing for TDDS(Transdermal drug delivery system) products as Patch, Plaster, Cataplasma - 3rd factory: Dedicated for anticancer as oral solution (Newly builted for DHP107 - world first oral paclitaxel solution)- Hyangnam Factory: Manufacturing for API and health supplementary and so on. Also, we are running 4subsidiaries company as below- DH Horim: Pharmaceutical wholesaler - Redox-Bio: Synthesizing of HA(Hyaluronic acid)/PDRN/Glutachione and related trading - S-Med: Medical information system contents service - C-Tri: R&D and pharmaceutical manufacturer focusing on Bio-products Among out products, most important product is world first oral paclitaxel solution DHP-107(Project name). This product would be get approval in Korea around 3Q of 2016 for Gastric cancer as first indication. This product adopt the our platform technology DHLASED(DaeHwa Lipid-bAsed Self-Emulsifying Drug delivery system) as first project. For more details and other business cooperation oppotunity, please kindly contact to below email address; crispaul@dhpharm.co.kr (Mr. Paul/Young-Sang Cho - Manager of Overseas Business Dept./ Business Development) Thanks and best regards,

201 to 500 staff

Gccl

Accelerate your global trials with GCCL - All-in-One Clinical Lab Solution (Central Lab + BA Lab + R&D) GCCL, a Lab CRO based in South Korea, specializing in clinical sample analysis services for all phases of trials. With an exclusive lab service available for clinical trials and a logistics system that meets global quality standards, GCCL is building trust with over 200 partners globally by providing a sample analysis and bioanalytical service spanning the entire cycle of clinical trials to meet customer demands.

51 to 200 staff

Organon Korea

& (1577-8582).(*- 9- 6, 5 – )

201 to 500 staff

Inventage Lab

Inventage Lab has the technology to mass-produce micro/nano drug delivery systems using microfluidics technology. Sustained-release injectables using polymeric microspheres have been commercialized, and lipid nano delivery systems such as liposome and LNP are now being manufactured.

51 to 200 staff

Jeil Pharmaceutical Co.,ltd

Jeil Pharmaceutical Co Ltd is a company based out of South Korea.

501 to 1000 staff

Koru Pharma Co., Ltd

Koru Pharma Co, Ltd. is a global biopharmaceutical company specialising in advanced aesthetic and regenerative treatments that inspire confidence and promote overall well-being. We develop and manufacture innovative medical products for corrective and cosmetic use, delivering noticeable improvements and long-lasting outcomes. Our portfolio includes biotechnologies engineered with a strong emphasis on safety, effectiveness, and consistency in clinical practice. Trusted by healthcare professionals in over 100 countries, we collaborate closely with practitioners to provide targeted, reliable solutions that address real-world dermatological needs. By continually investing in research and maintaining meaningful partnerships, we contribute to the evolution of aesthetic medicine — enhancing both practitioner capability and patient experience.

51 to 200 staff

Uppthera, Inc

UPPTHERA, Inc. is a pharmaceutical venture company aiming for new drug development employing 'targeted protein degradation' technology.

51 to 200 staff

Aimed Bio Inc

AIMEDBIO is a spin-off company from Samsung Medical Center with the sole purpose of pursuing after attainable treatment solutions to patients with refractory brain disease, including cancer, in hopes of providing better quality of life. Our primary objective is based on data-driven personalized treatment to address current medical unmet needs in the field of brain disease through international collaborations that we have solidified through years of close partnership. We have an excellent research team with profound achievements, own R&D pipelines with outstanding drug development platform and are building strong global networks with key opinion leaders in the field.

11 to 50 staff

Cho-A Pharmaceutical. Co., Ltd

Since our inaugural export to Vietnam in 1995, Cho A Pharm has consistently grown its global presence by distributing our products across various regions, including the Middle East, Asia, America, and South Africa. We have forged partnerships with over 40 overseas collaborators, including those in the USA, Guatemala, Iran, Vietnam, China, Georgia, and more. With our dedicated manufacturing facility, we offer a diverse range of both off-the-shelf and customized products, ensuring that we can meet your specific business needs efficiently and effectively.

201 to 500 staff

Embocaps

Founded in 1973, the Embocaps® by Suheung brand name is recognized globally as the premium capsule supplier of choice for companies that want the best. Specializing in the production of empty hard capsules for use in pharmaceutical and nutraceutical applications, Embocaps® by Suheung is the industry benchmark for quality.

501 to 1000 staff

Lotte Biologics

Founded in 2022 and headquartered in Seoul, South Korea, LOTTE Biologics operates integrated biologics facilities in the United States and South Korea. Through a unified Dual Hub Service model, LOTTE Biologics enhances supply security, supports manufacturing scalability, and maintains consistent quality standards across regions. LOTTE Biologics provides modular, phase-appropriate manufacturing solutions spanning preclinical through commercial stages, with proven capability in producing mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, and multispecific modalities. At the Syracuse Bio Campus in New York, LOTTE Biologics delivers high-quality GMP drug substance manufacturing supported by more than 62 global regulatory approvals. The site offers L of total capacity across eight L stainless steel bioreactors and includes analytical and warehouse infrastructure. In addition, the company has expanded into Antibody-Drug Conjugates (ADCs) through strategic investment in onsite conjugation suites, enabling a streamlined, end-to-end pathway from biologic drug substance production to ADC manufacturing within a single campus. In South Korea, LOTTE Biologics is constructing three advanced bio plants at the Songdo Bio Campus. With the first facility already underway and scheduled for operation in 2027, each plant will include eight L stainless steel bioreactors for commercial production, supported by multiple L bioreactors for clinical-scale needs. Collectively, these plants will provide a manufacturing volume exceeding in bioreactor capacity. Guided by the vision “Possibilities Beyond Limits,” LOTTE Biologics is committed to serving as a long-term, trusted partner, supporting efficient scale-up, dependable manufacturing execution, and the continuous advancement of clients’ therapeutic programs.

501 to 1000 staff

Pharmabcine Inc

PharmAbcine is a clinical stage public company developing next generation IgG based therapeutics to treat cancer, neovascular eye diseases, and vascular related unmet needs. PharmAbcine has its own HuPhage library and innovative selection system. This technology provides therapeutic antibodies for a wide spectrum of indications in oncology, immuno-oncology, ophthalmology, pulmonology etc. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state of the art antibody generation services. PharmAbcine has focused on the development of novel antibody therapeutics since the company’s foundation in 2008 and laid the groundwork for the commercialization of Olinvacimab, PMC-309, PMC-403, and PMC-402. We will also become an innovative global biotech company through the development of other new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s.

51 to 200 staff

Rudacure

RudaCure is a biotechnology company founded in 2018 that is developing treatments for incurable diseases with high unmet needs. Currently focusing on the development of two main assets (RCI001 & RCI002), with RCI001 being a treatment for Dry Eye Disease and RCI002 being a treatment for various pain diseases.

11 to 50 staff

Dongsung Bio Pharmaceutical Co., Ltd

Dongsung biopharmaceutical with 60 years of history provides customer-oriented total services and future-oriented marketing which covers cosmetics and finished medicine.

201 to 500 staff

Linical

Linical is a global Contract Research Organization (CRO) for full-service drug development, with a proven record of helping biopharmaceutical companies successfully navigate the clinical development journey. Linical is headquartered in Japan with a significant presence across all major markets including North America, Europe, and Asia-Pacific. Linical provides a full spectrum of drug development services from early stage to large-scale, multinational studies. Our areas of focus include Phase I-IV studies in oncology, neurology & psychiatry, immunology & vaccine, and endocrinology & metabolic diseases. Combining strong business perspective with clinical and medical expertise, our team goes beyond operational excellence providing flexibility, guidance, and key strategies to successfully overcome drug development and regulatory challenges. We strive to offer professional, high-quality services with the personal attention needed in a constantly evolving pharmaceutical and biotech market. Rather than be all things to the market, this intentional design allows us to provide our clients the right size, right reach, and right team.

501 to 1000 staff

Ono Pharma Korea Co., Ltd

OPDIVO 2005 5 Medarex PD-1 2014 7 PD-1. 2014 12 2015 3 PD-1. PD-1 2013 Science "Breakthrough of the year". OPDIVO (ASCO)(ESMO). BMS. unmet medical needs.

11 to 50 staff

Pharmbio Korea

A pharmaceutical company committed to importing, exporting, manufacturing, and distributing innovative drugs to fullfill unmet medical needs in Korea. We started our business in targeting then niche market for treatment of urinary stones and cystitis. After initial success in urologic field, we're expanding our scope of service to Gastrointestinal/General Surgery, Ob-Gyn, orthopedics, oncology, and immunology and are growing in average revenue by 43% every year since 2003. More details will be provided upon request.

201 to 500 staff

Standigm

Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing. Learn more at

51 to 200 staff

Atgc Co.,ltd

ATGC develops Botulinum Toxin A type (900 KDa and 150 KDa) and aims to bio-pharmaceutical products. We are looking for global partners with our future pipeline. Thanks.

11 to 50 staff

Geoyoung, An Mbk Partners Private Equity Portfolio Company

Korea's No1. Healthcare Partner

1001 to 5000 staff

Prestige Biopharma Group Prestige Biopharma Prestige Biologics

Prestige Biopharma (PBP) is an innovative biopharmaceutical company specializing in the discovery and development of innovative biologics and biosimilars. PBP1510 (Ulenistamab) is the First-in-Class Pancreatic Cancer drug which is on the stage of 1/2a global clinical phase. Based on our innovative biomarker, PAUF, we are continuing the challenge for overcoming hard-to-treat diseases such as pancreatic cancer. We are developing biosimilars to contribute on the patient's drug accessibility. Over 18 biosimilars we have been developing since 2015. And also, we are expanding the application of PAUF biomarker to the diagnostics. To expand the effectiveness of pancreatic cancer treatment, we are developing the diagnostic device. The primary focus of current PBP’s R&D is oncology and immune disorders, developing new and similar antibody drugs for solid tumor, pancreatic cancer, and arthritis. In parallel with our efforts to enhance safety, efficacy, and affordability of existing antibody therapeutics, PBP thrives to search for new targets and candidates with a goal to free mankind from devastating diseases Established on core values cherishing life and fostering the spirit of philanthropy, Prestige BioPharma promises to grow everyday to make our dream come true.

201 to 500 staff

Shinpoong Pharmaceutical Co.,ltd

SHINPOONG PHARMACEUTICAL CO,LTD. is a pharmaceuticals company based out of 733-23 Yoksam-Dong,Kangnam-Gu,Seoul, Seoul, South Korea.

11 to 50 staff

Whan In Pharm. Co., Ltd

Whan In Pharm. Co, Ltd. is a pharmaceutical company in South Korea, established in 1978. The company currently manufactures and distributes various products across several therapeutic areas, such as cardiovascular diseases and gastrointestinal disorders, but is especially specialized in the Central Nervous System (CNS), including antipsychotics, antidepressants, and antiepileptics. Whan In Pharm. Co, Ltd. is dedicated to fulfilling its social role of contributing to a healthier society by producing and supplying high-quality medicines.

501 to 1000 staff

Duchembio Co., Ltd

Developing new radiopharmaceuticals for cancer diagnosis & treatment, and achieving successful commercialization locally & globally

51 to 200 staff

Korea Drug Development Fund

Established in September 2011, Korea Drug Development Fund (KDDF) is a government-initiated drug development program. It aims to transform Korea into the global leader for new drug development. It has a budget of 1 billion US dollars to enhance national competitiveness in the global arena. KDDF is now backed by three health-related Korean ministries: the Ministry of Science, ICT, and Future Planning, the Ministry of Trade, Industry, and Energy, and the Ministry of Health and Welfare. KDDF aims to enhance development of at least 10 new global blockbuster drugs by the year 2020.

11 to 50 staff

Mdimune

BioDrone®)

11 to 50 staff

Medirama Inc

Founded in August 2021 by experienced professionals in clinical development, business development and commercialization. MediRama offers the best fit services for clients by maximizing the value of their assets and technologies from well-thought-out development strategies to seamless business development. MediRama’s approach is based on deep understanding of and expertise in clinical development of drugs, diseases and clinical practice in alignment with ultimate patient benefits. Our definition of success is to enable “NDA/BLA” for compounds in development. MediRama leads the success as a supporter in clinical and business development. Our expertise comes from successful experiences in clinical oncology and related basic sciences, and in the pharmaceutical industry and related settings, supported by a strong network in various locations worldwide and in different functions

11 to 50 staff

Onconic Therapeutics

11 to 50 staff

Phil International

Phil international is exportation and R&D company of pharmaceutical products. we have worldwide network with production, marketing and sales in pharmaceutical and dietary supplement industry. Our pharmaceutical products are manufactured under NSF-GMP, EU-GMP, WHO-GMP accreditation. e have around 250 products manufactured in-house and we keep QC to the highest level. For more than 20 years, Phil international has worked to make a difference for all who rely on us. To learn more, please visit

51 to 200 staff

Samil Pharmaceutical Co Ltd

Samil Pharmaceutical Co Ltd is a company based out of South Korea.

201 to 500 staff

Sk Plasma

Developer of plasma-derived medicine intended to promote human health and protect the environment. The company carries a plasma fractionation business and offers plasma-derived products that are essential medicines to treat diseases that can be directly linked to human life, such as congenital immunodeficiency diseases and hemophilia, enabling doctors to create social value to protect the health of human lives.

201 to 500 staff

D&d Pharmatech

D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers. Close collaborations with leading research institutes worldwide provide us with a unique opportunity to accelerate translation of cutting-edge research into revolutionary lifesaving therapeutic products for patients.

11 to 50 staff

Jnpmedi

Founded in July 2020, JNPMEDI has been putting effort on bringing disruption on healthcare industry via integrating digital technologies to clinical research & trial operations. With the launch of Maven CDMS™ and Maven clinical cloud solutions, we are taking steps forward to digitally transform the capabilities of regulatory authority, pharmaceuticals and CROs for better execution, management, monitoring, and audit of clinical trials. JNPMEDI Inc. is consist of c-suite officers with experiences across the span of management consulting, digital transformation strategy, cutting-edge tech development, clinical operations and pharmaceuticals. We understand technologies as well as conventional clinical operations and delivering high performance to clinical ambiences to ultimately help general people in the globe. We propagate our core capabilities via operating divisions of R&D laboratory, business development, consulting and clinical operation support.

51 to 200 staff

Kanaph Therapeutics

Kanaph Therapeutics is a drug discovery and pre-clinical stage biotech based in Korea, with a large and small molecule two-track strategy for the development of first-in-class and best-in-class therapeutics in immuno-oncology, targeted therapy and autoimmune (ophthalmology) diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.

11 to 50 staff